mTOR inhibitors: all 1,276 studies that test it

Page 5 of 13. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.

• Tacrolimus to Sirolimus Conversion for Delayed Graft FunctionTerminatedNCT00931255Phase 4Results posted
• Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast CancerCompletedNCT00930930Phase 2Results posted
• Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With LymphomaCompletedNCT00928018Phase 3Results posted
• Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney CancerCompletedNCT00923845Phase 2Results posted
• Sirolimus and Pemetrexed to Treat Non-Small Cell Lung CancerTerminatedNCT00923273Phase 1/2Results posted
• Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung CancerTerminatedNCT00921310Phase 1/2Results posted
• Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2/3Results posted
• Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer PatientsCompletedNCT00919035Phase 2Results posted
• Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast CancerCompletedNCT00915603Phase 2Results posted
• Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast CancerCompletedNCT00912340Phase 2Results posted
• Sirolimus as Therapeutic Approach to UveitisCompletedNCT00908466Phase 1Results posted
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell CarcinomaCompletedNCT00903175Phase 2Results posted
• Kidney Biopsy Controlled Trial of Calcineurin Inhibitor WithdrawalCompletedNCT00896012Phase 4Results posted
• Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant RecipientsCompletedNCT00895583Phase 4Results posted
• Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate CancerTerminatedNCT00887640Phase 2Results posted
• Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerCompletedNCT00886691Phase 2Results posted
• Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)CompletedNCT00879333Phase 3Results posted
• Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer PatientsTerminatedNCT00877773Phase 1/2Results posted
• Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00876395Phase 3Results posted
• Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT00869999Phase 2Results posted
• Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft RecipientsCompletedNCT00866879Phase 4Results posted
• Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedNCT00866684Phase 4Results posted
• Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleCompletedNCT00863655Phase 3Results posted
• The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular DegenerationTerminatedNCT00857259Phase 2Results posted
• RAD001 and Erlotinib in Patients With Neuroendocrine TumorsTerminatedNCT00843531Phase 2Results posted
• Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney RemovalTerminatedNCT00831480Phase 2Results posted
• Trial of RAD001 in Triple Negative Metastatic Breast CancerTerminatedNCT00827567Phase 2Results posted
• Biomarker Trial of Everolimus in Patients With Advanced Renal Cell CarcinomaCompletedNCT00827359Phase 2Results posted
• Everolimus in Treating Patients With Recurrent Low-Grade GliomaCompletedNCT00823459Phase 2Results posted
• Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate CancerCompletedNCT00814788Phase 2Results posted
• Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers SyndromeTerminatedNCT00811590Phase 2Results posted
• RAD001(Everolimus) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00809185Phase 2Results posted
• Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk NeuroblastomaTerminatedNCT00808899Phase 2Results posted
• RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBMCompletedNCT00805961Phase 2Results posted
• Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00805129Phase 2Results posted
• Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT00803010Phase 2Results posted
• Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)CompletedNCT00795886Phase 2Results posted
• Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)CompletedNCT00790400Phase 3Results posted
• Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapyCompletedNCT00790036Phase 3Results posted
• Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)CompletedNCT00789828Phase 3Results posted
• Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade GliomasCompletedNCT00782626Phase 2Results posted
• Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell CarcinomaCompletedNCT00782275Phase 2Results posted
• Prospective Study of Rapamycin for the Treatment of SLECompletedNCT00779194Phase 2Results posted
• Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00775593Phase 2Results posted
• S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By SurgeryCompletedNCT00770120Phase 2Results posted
• Treatment of Patients With RAD001 With Progressive SarcomaCompletedNCT00767819Phase 2Results posted
• Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMDCompletedNCT00766649Phase 1/2Results posted
• A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced SarcomaCompletedNCT00743509Phase 2Results posted
• Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial CancerCompletedNCT00729586Phase 2Results posted
• RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line TreatmentCompletedNCT00729482Phase 2Results posted
• Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT00723255Phase 2Results posted
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCompletedNCT00719264Phase 2Results posted
• Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving MyforticCompletedNCT00713284Phase 4Results posted
• Sirolimus to Treat Diabetic Macular EdemaCompletedNCT00711490Phase 1/2Results posted
• Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® TherapyCompletedNCT00702052Phase 2Results posted
• RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in EuropeCompletedNCT00688753Phase 2Results posted
• RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in EuropeCompletedNCT00688623Phase 2Results posted
• Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma MultiformeCompletedNCT00672243Phase 2Results posted
• Raptiva and Sirolimus in Islet Transplantation for Type 1 DiabetesTerminatedNCT00672204Phase 1/2Results posted
• Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and CorticosteroidsCompletedNCT00658320Phase 3Results posted
• Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)TerminatedNCT00651482Phase 2Results posted
• Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic CancerTerminatedNCT00640978Phase 2Results posted
• Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant RecipientsCompletedNCT00634920Phase 4Results posted
• A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform NeurofibromasCompletedNCT00634270Phase 2Results posted
• Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00634244Phase 2Results posted
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma SubjectsCompletedNCT00631371Phase 3Results posted
• RAD001 and Bicalutamide for Androgen Independent Prostate CancerCompletedNCT00630344Phase 2Results posted
• RAD001 in Patients With Metastatic, Hormone-Refractory Prostate CancerCompletedNCT00629525Phase 2Results posted
• Rapamycin for Prevention of Chronic Graft-Versus-Host DiseaseTerminatedNCT00623012Phase 1/2Results posted
• Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant RecipientsCompletedNCT00622869Phase 3Results posted
• Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine CarcinomaCompletedNCT00607113Phase 2Results posted
• Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + EverolimusCompletedNCT00597506Phase 2Results posted
• RAD001 Plus Bevacizumab in Metastatic MelanomaCompletedNCT00591734Phase 2Results posted
• Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral InfectionTerminatedNCT00582738Phase 2Results posted
• RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine TumorsCompletedNCT00576680Phase 1/2Results posted
• Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor FailureCompletedNCT00570921Phase 2Results posted
• Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT00553150Phase 1/2Results posted
• Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting StentsCompletedNCT00552669Phase 4Results posted
• Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell TransplantationTerminatedNCT00548717Phase 2Results posted
• Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas RecipientsCompletedNCT00533442Phase 2Results posted
• Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell CancerCompletedNCT00529802Phase 2Results posted
• Everolimus in Treating Patients With Newly Diagnosed Localized Prostate CancerTerminatedNCT00526591Phase 2Results posted
• Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by SurgeryCompletedNCT00521001Phase 2Results posted
• RAD001 in Advanced Hepatocellular CarcinomaCompletedNCT00516165Phase 1/2Results posted
• Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)TerminatedNCT00515086Phase 2Results posted
• Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose RegimenCompletedNCT00514514Phase 3Results posted
• Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine TumorsCompletedNCT00510068Phase 3Results posted
• Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)TerminatedNCT00506948Phase 2Results posted
• Sirolimus in Treating Patients With Advanced Pancreatic CancerCompletedNCT00499486Phase 2Results posted
• Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell CarcinomaCompletedNCT00494091Phase 2Results posted
• Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple MyelomaCompletedNCT00483262Phase 1/2Results posted
• Study Evaluating Rapamune® Maintenance RegimenCompletedNCT00478608Phase 3Results posted
• Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaCompletedNCT00474929Phase 1/2Results posted
• Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line SunitinibCompletedNCT00474786Phase 3Results posted
• The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate CancerCompletedNCT00459186Phase 1/2Results posted
• Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast CancerCompletedNCT00458237Phase 1/2Results posted
• Everolimus (RAD001) as Therapy for Patients With Systemic MastocytosisCompletedNCT00449748Phase 2Results posted
• Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous TreatmentCompletedNCT00436618Phase 2Results posted
• Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT00429793Phase 2Results posted
• Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast CancerCompletedNCT00426556Phase 1Results posted

← mTOR inhibitors overview